Editorial Board Member

Dr. Bril has always had a strong interest in clinical research and biostatistics, embarking early-on on a career as a physician-scientist. After completing internal medicine residency at Instituto Universitario CEMIC, Buenos Aires, Argentina, he joined the Division of Endocrinology, Diabetes and Metabolism at the University of Florida in Gainesville, Florida, USA, in 2012 as a Post-Doctoral Associate. Later, Dr. Bril stayed as a faculty member until 2020, when he moved to University of Alabama at Birmingham, Birmingham, AL, USA. Dr. Bril’s main research interest has been to understand the metabolic mechanisms that promote the progression from isolated steatosis to NASH and advanced fibrosis. He has also focused on identifying diagnostic biomarkers and pharmacological approaches that could help us change the natural history of this disease. His research combines the use of stable isotopes to assess nutrient turnover, as well as novel imaging techniques to characterize the severity of liver disease. His work has resulted in significant peer-reviewed articles in the field, including two randomized controlled trials on the use of pioglitazone in patients with NASH. He has also reported on how the presence of NAFLD and/or NASH influences changes in dyslipidemia, diabetes control, and insulin resistance, all mechanisms potentially leading to increased cardiovascular risk in patients with NAFLD. Dr. Bril has also focused on the assessment of potential new plasma and imaging biomarkers for the diagnosis of NAFLD and NASH. He serves as reviewer, and participates in the editorial board, of important journals in the field of diabetes and liver disease.

insulin resistance, NAFLD, NASH, liver steatosis, fatty liver disease, lipotoxicity